PSNL News and Press, Personalis Inc. From 10/26/23

NeXT Personal Dx is an ultra-sensitive test for detecting cancer from a blood sample Clinical data from groundbreaking TRACERx lung cancer study demonstrates significant sensitivity and lead time improvements in detecting cancer Personalis, Inc . (Nasdaq: PSNL), a leader i...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2023 financial results on Tuesday, November 7, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p...

NeXT Personal ® ctDNA assay shown to be more sensitive and predictive of clinical outcomes in early-stage lung cancer patients Demonstrates importance of an ultra-sensitive ctDNA approach Personalis, Inc . (Nasdaq: PSNL), a leader in precision oncology, today announ...

Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc . (Nasdaq: PSNL), a leader...

2023-09-06 08:27:34 ET Summary Personalis is a small-cap stock specializing in cancer genomics, with an advanced cancer diagnostics platform. The company reported significant losses in Q2 earnings but maintains a robust financial standing and expects future revenue growth. Per...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the 21 st Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023 at 4:55 p.m. Eastern Time in New York, NY at the Sheraton...

NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is subje...

2023-08-08 23:24:10 ET Personalis, Inc. (PSNL) Q2 2023 Earnings Conference Call August 08, 2023 05:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - CMO and EVP, R&D Conferenc...

2023-08-08 17:04:02 ET Personalis press release ( NASDAQ: PSNL ): Q2 GAAP EPS of -$0.50 beats by $0.04 . Revenue of $16.7M (-8.2% Y/Y) beats by $0.21M . Cash, cash equivalents, and short-term investments of $137.2 million as of June 30, 2023. Third Quar...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2023 and provided recent business highlights. Recent Business Updates Announced a collaboration with National Cancer Center H...